---
title: "Nephro Care India Ltd (NEPHROCARE) — Share Price, Financials & Analysis"
symbol: "NEPHROCARE"
company: "Nephro Care India Ltd"
canonical: "https://tapetide.com/stocks/NEPHROCARE"
isin: "INE0SUN01013"
nse_symbol: "NEPHROCARE"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 152.58
generated_at: "2026-09-13T19:07:46.313Z"
---

# Nephro Care India Ltd (NEPHROCARE)

Canonical page: https://tapetide.com/stocks/NEPHROCARE

## Company

- **NSE Symbol:** NEPHROCARE
- **ISIN:** INE0SUN01013
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-07-05
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** nephrocareindia.com

## About

Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes
in the treatment of kidney- related diseases[1]

## Latest Price

- **Price:** ₹93.2
- **Change:** +1.75 (+1.91%)
- **Open:** ₹91.45
- **Day High:** ₹94.45
- **Day Low:** ₹91.45
- **Previous Close:** ₹91.45
- **Volume:** 28800
- **As Of:** 2026-09-11T09:59:44+00:00

## Key Fundamentals

Observed at 2026-09-11T04:40:40.974928Z.

- **Market Cap:** ₹152.58 Cr
- **Classification:** SME
- **P/E (reported):** 44.8
- **Book Value:** ₹34.49
- **Price to Book:** 2.65
- **Dividend Yield:** 0%
- **ROE:** 6.8%
- **ROCE:** 9.1%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹88.73 Cr
- **Net Income:** ₹3.21 Cr
- **EBITDA:** ₹8.32 Cr
- **52-Week High:** ₹170.5
- **52-Week Low:** ₹50.05
- **RSI (14):** 54.26

## Tapetide Score

- **Score:** 57 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 77.8 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 86.2 | 9% |
| growth | 98.9 | 9% |
| momentum | 79.33 | 12% |
| ownership | 54.6 | 24% |
| quality | 73.84 | 22% |
| valuation | 25.46 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.7% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 759.34% | 89.81% | — |
| ebitda margin growth | 31.03% | -40.75% | -62.78% | 146.52% |
| net income growth | 60% | -10.83% | 12% | 106% |
| revenue growth | 6.52% | 86.41% | 73% | 118% |
| roce | — | -78.21% | -82.9% | 24.8% |
| roe | — | -77.31% | 43.53% | -89.07% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- |
| Sales | 17.33 | 22.66 | 26.75 | 29.19 |
| Expenses | 16.73 | 20.75 | 24.73 | 25.57 |
| Operating Profit | 0.6 | 1.91 | 2.02 | 3.62 |
| OPM % | 3.46 | 8.43 | 7.55 | 12.4 |
| Other Income | 0.05 | 0.08 | 0.83 | 0.22 |
| Interest | 0.14 | 0.03 | -0.01 | 0.03 |
| Depreciation | 1.16 | 1.4 | 1.56 | 1.19 |
| Profit before tax | -0.65 | 0.56 | 1.3 | 2.62 |
| Tax % | 0 | 25 | 23.08 | 38.17 |
| Net Profit | -0.65 | 0.42 | 1 | 1.61 |
| EPS in Rs | -0.39 | 0.25 | 0.61 | 0.98 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | 88.73 |
| Expenses | 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | 80.41 |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 | 8.32 |
| OPM % | 3.7 | 8.24 | 4.09 | 20.07 | 23.76 | 12.75 | 9.38 |
| Other Income | 0.01 | 0.01 | -0.01 | 0 | 0.28 | 1.53 | 1.55 |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 | 0.16 |
| Depreciation | 0 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 | 5.07 |
| Profit before tax | -0.01 | 0.12 | 0 | 2.58 | 6.13 | 4.83 | 4.64 |
| Tax % | 0 | 25 | — | 7.75 | 28.06 | 24.64 | 27.37 |
| Net Profit | -0.01 | 0.09 | -0.01 | 2.37 | 4.41 | 3.64 | 3.37 |
| EPS in Rs | -10 | 90 | -0.2 | 47.4 | 3.71 | 2.21 | 2.04 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.01 | 0.01 | 0.5 | 0.5 | 11.9 | 16.49 | 16.49 |
| Reserves | 0.07 | 0.01 | 0 | 2.03 | 3.12 | 37 | 40.37 |
| Borrowings | 0.4 | 0.69 | 2.54 | 2.48 | 0 | 0 | 0 |
| Other Liabilities | 0.3 | 0.42 | 1.6 | 3.25 | 5.94 | 14.79 | 15.81 |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
| Fixed Assets | 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.48 | 34.12 |
| CWIP | 0 | 0.45 | 1.9 | 0 | 0.86 | 0.61 | 0.43 |
| Investments | 0.24 | 0 | 0 | 2 | 6.51 | 18.58 | 11.82 |
| Other Assets | 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | 26.3 |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | 0.23 | 0.62 | 4.12 | 0.91 | 7.82 | 2.21 |
| Cash from Investing Activity | — | -0.06 | -2.81 | -2.33 | -7.54 | -39.56 | -0.48 |
| Cash from Financing Activity | — | 0.28 | 2.32 | -0.08 | 5.6 | 35.1 | 0 |
| Net Cash Flow | — | 0.44 | 0.13 | 1.71 | -1.03 | 3.37 | 1.73 |
| Free Cash Flow | — | 0.16 | -2.28 | 3.62 | -2.38 | -21.98 | -5.59 |
| CFO/OP | — | 133 | 493 | 121 | 50 | 154 | 48 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 0 | 0 | 20.28 | 0.85 | 2.01 | 25.61 | 24.85 |
| Inventory Days | — | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | 31.68 |
| Days Payable | — | 94.19 | 113.45 | 69.03 | 75.17 | 107.32 | 92.84 |
| Cash Conversion Cycle | 0 | -85.36 | -51.24 | -32.93 | -59.09 | -47.33 | -36.31 |
| Working Capital Days | -168.98 | -88.24 | -124.87 | -56.81 | -36.86 | -51.23 | 37.1 |
| ROCE % | — | 25.21 | 1.6 | 65.84 | 60.41 | 11.27 | 8.7 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 85.02% | 61.38% | 61.38% | 61.44% | 61.47% | 61.71% | 61.71% |
| FIIs | 0% | 3.92% | 4.06% | 3.5% | 3.47% | 0.73% | 0.96% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 1.3% | 1.29% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 24.6% | 25.72% | 27.07% | 27.66% | 30.32% | 30.34% |
| Others | 14.98% | 10.1% | 8.84% | 7.99% | 7.4% | 5.94% | 5.69% |
| No. of Shareholders | 95 | 850 | 1077 | 1391 | 1644 | 1845 | 1900 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 7 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 92.51 | Buy |
| EMA (10) | 90.93 | Buy |
| SMA (20) | 91.57 | Buy |
| EMA (20) | 89.46 | Buy |
| SMA (50) | 78.55 | Buy |
| EMA (50) | 83.01 | Buy |
| SMA (100) | 77.39 | Buy |
| EMA (100) | 81.44 | Buy |
| SMA (200) | 86.77 | Buy |
| EMA (200) | 89.66 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 56.36 | Neutral |
| MACD (12,26,9) | 3.04 | Sell |
| Stochastic (14,3,3) | 42.54 | Neutral |
| ADX (14) | 24.45 | Neutral |
| Williams %R (14) | -48.82 | Neutral |
| ATR (14) | 6.48 | High Volatility |
| ROC (12) | -5.52 | Sell |
| Stoch RSI (14) | 42.21 | Neutral |
| UO (7,14,28) | 46 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no dematerialisation requests received. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no dematerialisation requests received.](https://nsearchives.nseindia.com/corporate/NEPHRO_09072026145704_NCIL_Reg_74_5_.pdf) |
| 9 July 2026 - Revised audited standalone and consolidated results for year ended 31 March 2026 submitted after NSE queries. | [Reply to Clarification- Financial results 9 July 2026 - Revised audited standalone and consolidated results for year ended 31 March 2026 submitted after NSE queries.](https://nsearchives.nseindia.com/corporate/NEPHRO_08072026172150_NCIL_Reply_to_email_dated_29062026.pdf) |
| 9 April 2026 - Regulation 74(5) certificate filed for quarter ended 31 March 2026; no rematerialisation requests. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 April 2026 - Regulation 74(5) certificate filed for quarter ended 31 March 2026; no rematerialisation requests.](https://nsearchives.nseindia.com/corporate/NEPHRO_09042026160011_NCIL_Disclosure_under_Reg_74_5_.pdf) |
| 9 April 2026 - Promoters disclosed 1,01,74,000 shares held as of March 31, 2026; no encumbrance during FY26. | [Disclosure under SEBI Takeover Regulations 9 April 2026 - Promoters disclosed 1,01,74,000 shares held as of March 31, 2026; no encumbrance during FY26.](https://nsearchives.nseindia.com/corporate/team_sandeshc_08042026115357_Declaration9.pdf) |
| 9 April 2026 - Company confirms corporate governance regulations 17-27 not applicable for quarter and year ended 31 March 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 9 April 2026 - Company confirms corporate governance regulations 17-27 not applicable for quarter and year ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/NEPHRO_09042026160227_Disclosure_under_Reg_27_2__Non_applicability.pdf) |
| 8 Sep - DAD unit in Kolkata will cease operations and vacate by 15 September 2026. | [Closure of operations 8 Sep - DAD unit in Kolkata will cease operations and vacate by 15 September 2026.](https://nsearchives.nseindia.com/corporate/NEPHRO_08092026115740_NCIL_Discontinuation_of_DAD_Unit.pdf) |
| 7 Aug - Submitted IPO proceeds utilization statement to 30 June 2026; no deviation reported. | [Statement of deviation(s) or variation(s) under Reg. 32 7 Aug - Submitted IPO proceeds utilization statement to 30 June 2026; no deviation reported.](https://nsearchives.nseindia.com/corporate/NEPHRO_07082026172202_NCIL_Utilisation_of_issue_proceeds.pdf) |
| 7 Aug - Board approved Q1 FY27 results; Tulip Hospital Ranchi discontinued; NSE non-compliance notice noted; AGM on 25 Sept 2026. | [Outcome of Board Meeting 7 Aug - Board approved Q1 FY27 results; Tulip Hospital Ranchi discontinued; NSE non-compliance notice noted; AGM on 25 Sept 2026.](https://nsearchives.nseindia.com/corporate/NEPHRO_07082026172757_NCIL_Outcome_of_BM.pdf) |
| 7 Aug - Board approved Q1 FY27 results, Tulip Hospital closure, Malda HOMA, Ranchi collaboration, AGM on 25 Sept 2026. | [Outcome of Board Meeting 7 Aug - Board approved Q1 FY27 results, Tulip Hospital closure, Malda HOMA, Ranchi collaboration, AGM on 25 Sept 2026.](https://nsearchives.nseindia.com/corporate/NEPHRO_07082026171907_NCIL_Outcome_of_BM.pdf) |
| 6 March 2026 - Company clarifies submission of Certificate of Utilization of Proceeds for quarter ended Dec 2025; acknowledgment attached. | [Reply to Clarification- Financial results 6 March 2026 - Company clarifies submission of Certificate of Utilization of Proceeds for quarter ended Dec 2025; acknowledgment attached.](https://nsearchives.nseindia.com/corporate/NEPHRO_05032026153649_NCIL_Reply_of_email_dated_05032026.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30660_NEPHROCARE_2025_2026_A_3880390_26082026160946.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27246_NEPHROCARE_2024_2025_A_02082025134502.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25225_NEPHROCARE_2023_2024_28082024162322.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Aug 2025 | [Concall - Aug 2025](https://nsearchives.nseindia.com/corporate/NEPHRO_12082025094049_Nephrocare_Investor_ppt.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:07:46.313Z.